Market Overview

Amicus Therapeutics to Discuss Regulatory Strategy on 8:00 AM ET Conference Call

Amicus Therapeutics (NASDAQ: FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, announced that John F. Crowley, Chairman and Chief Executive Officer, will host a conference call at 8:00 a.m. ET this morning. Mr. Crowley will highlight the regulatory strategy for migalastat HCl monotherapy for Fabry disease following a recent Type C meeting with the U.S. Food and Drug Administration (FDA).

Interested participants and investors may access the conference call this morning at 8:00 a.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international). An audio-visual webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at http://www.amicusrx.com, and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download and install any necessary software.

A telephonic replay of the call will be available for seven days beginning at 11:00 a.m. ET today. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code 97032659.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The

See full press release

Posted-In: News Guidance Management

 

Related Articles (FOLD)

Around the Web, We're Loving...

Get Benzinga's Newsletters